BACKGROUND: It remains unknown as to whether the antipsychotic dose needed for the acute-phase treatment of schizophrenia is also necessary for relapse prevention. AIM: To compare the efficacy between standard dose [(World Health Organization daily defined dose (DDD)] vs low dose (≥50% to <1 DDD) or very low dose (<50% DDD) for relapse prevention in schizophrenia. DATA SOURCE: Double-blind, randomized, controlled trials with a follow-up duration of ≥24 weeks, including ≥2 dosage groups of the same antipsychotic drug for relapse prevention in schizophrenia, were searched using MEDLINE, the Cochrane Central Register of Controlled Trials, and EMBASE (last search: August 2009). DATA EXTRACTION: Data on overall treatment failure, hospitalization, relapse, and dropouts due to side effects were extracted and combined in a meta-analysis. DATA SYNTHESIS: Thirteen studies with 1395 subjects were included in this meta-analysis. Compared with the standard-dose treatment, the low-dose therapy did not show any statistically significant difference in overall treatment failure or hospitalization, while the standard dose showed a trend-level (P = .05) superiority in risk of relapse. The very low-dose group was inferior to the standard-dose group in all efficacy parameters. No significant difference was found in the rate of dropouts due to side effects between either standard dose vs low dose or very low dose. CONCLUSIONS: Although antipsychotic treatment with ≥50% to <1 DDD may be as effective as standard-dose therapy, there are insufficient clinical trial data to draw firm conclusions on standard- vs low-dose maintenance antipsychotic therapy for schizophrenia.
BACKGROUND: It remains unknown as to whether the antipsychotic dose needed for the acute-phase treatment of schizophrenia is also necessary for relapse prevention. AIM: To compare the efficacy between standard dose [(World Health Organization daily defined dose (DDD)] vs low dose (≥50% to <1 DDD) or very low dose (<50% DDD) for relapse prevention in schizophrenia. DATA SOURCE: Double-blind, randomized, controlled trials with a follow-up duration of ≥24 weeks, including ≥2 dosage groups of the same antipsychotic drug for relapse prevention in schizophrenia, were searched using MEDLINE, the Cochrane Central Register of Controlled Trials, and EMBASE (last search: August 2009). DATA EXTRACTION: Data on overall treatment failure, hospitalization, relapse, and dropouts due to side effects were extracted and combined in a meta-analysis. DATA SYNTHESIS: Thirteen studies with 1395 subjects were included in this meta-analysis. Compared with the standard-dose treatment, the low-dose therapy did not show any statistically significant difference in overall treatment failure or hospitalization, while the standard dose showed a trend-level (P = .05) superiority in risk of relapse. The very low-dose group was inferior to the standard-dose group in all efficacy parameters. No significant difference was found in the rate of dropouts due to side effects between either standard dose vs low dose or very low dose. CONCLUSIONS: Although antipsychotic treatment with ≥50% to <1 DDD may be as effective as standard-dose therapy, there are insufficient clinical trial data to draw firm conclusions on standard- vs low-dose maintenance antipsychotic therapy for schizophrenia.
Authors: N R Schooler; S J Keith; J B Severe; S M Matthews; A S Bellack; I D Glick; W A Hargreaves; J M Kane; P T Ninan; A Frances; M Jacobs; J A Lieberman; R Mance; G M Simpson; M G Woerner Journal: Arch Gen Psychiatry Date: 1997-05
Authors: C M Beasley; M A Dellva; R N Tamura; H Morgenstern; W M Glazer; K Ferguson; G D Tollefson Journal: Br J Psychiatry Date: 1999-01 Impact factor: 9.319
Authors: D L Zimbroff; J M Kane; C A Tamminga; D G Daniel; R J Mack; P J Wozniak; T B Sebree; B A Wallin; K B Kashkin Journal: Am J Psychiatry Date: 1997-06 Impact factor: 18.112
Authors: L B Inderbitzin; R R Lewine; G Scheller-Gilkey; C D Swofford; G J Egan; B A Gloersen; B P Vidanagama; C Waternaux Journal: Am J Psychiatry Date: 1994-12 Impact factor: 18.112
Authors: D C Goff; T Posever; L Herz; J Simmons; N Kletti; K Lapierre; K D Wilner; C G Law; G N Ko Journal: J Clin Psychopharmacol Date: 1998-08 Impact factor: 3.153
Authors: Henrik Berg Rasmussen; Sally Timm; August G Wang; Karen Søeby; Henrik Lublin; Mogens Fenger; Ralf Hemmingsen; Thomas Werge Journal: Am J Psychiatry Date: 2006-03 Impact factor: 18.112
Authors: D V Jeste; M P Caligiuri; J S Paulsen; R K Heaton; J P Lacro; M J Harris; A Bailey; R L Fell; L A McAdams Journal: Arch Gen Psychiatry Date: 1995-09
Authors: Xenia M Hart; Christoph Hiemke; Luzie Eichentopf; Xenija M Lense; Hans Willi Clement; Andreas Conca; Frank Faltraco; Vincenzo Florio; Jessica Grüner; Ursula Havemann-Reinecke; Espen Molden; Michael Paulzen; Georgios Schoretsanitis; Thomas G Riemer; Gerhard Gründer Journal: Psychopharmacology (Berl) Date: 2022-10-05 Impact factor: 4.415
Authors: Kazunari Yoshida; Robert R Bies; Takefumi Suzuki; Gary Remington; Bruce G Pollock; Yuya Mizuno; Masaru Mimura; Hiroyuki Uchida Journal: Schizophr Res Date: 2014-02-01 Impact factor: 4.939
Authors: Heidi Taipale; Antti Tanskanen; Jurjen J Luykx; Marco Solmi; Stefan Leucht; Christoph U Correll; Jari Tiihonen Journal: Schizophr Bull Date: 2022-06-21 Impact factor: 7.348
Authors: Michael Odenwald; Birke Lingenfelder; Wolfgang Peschel; Farhan Adam Haibe; Abdirisak Mohamed Warsame; Ahmed Omer; Judith Stöckel; Anna Maedl; Thomas Elbert Journal: Int J Ment Health Syst Date: 2012-07-02
Authors: Peta-Gaye L Thomas-Brown; Jacqueline S Martin; Clayton A Sewell; Wendel D Abel; Maxine D Gossell-Williams Journal: Front Pharmacol Date: 2018-07-18 Impact factor: 5.810